Claris Biotherapeutics closed a $118 million Series B to advance CSB-001 (oremepermin alfa ophthalmic solution) toward pivotal trials in limbal stem cell deficiency. The company’s proof-of-concept readout showed improvements in visual acuity, and Claris plans to start clinical trials in the first half of 2027. Claris’ therapy is designed as an eye drop containing recombinant human deleted hepatocyte growth factor (dHGF), aiming to promote corneal epithelial regeneration while modulating inflammation and fibrosis. If approved, it would become the first pharmacologic treatment option for LSCD, replacing reliance on limbal stem cell transplantation. Strategically, the funding combines late-stage financing with executive leadership updates, aligning budget and oversight with the pivot from signal-building into confirmatory study planning.